Latest Strategy Changes News

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Michael Hill International reported a 3% rise in group sales and a 28.6% jump in comparable EBIT for the half-year ended December 2025, driven by strong performances across Australia, Canada, and New Zealand. Despite improved earnings and cash flow, the board has opted to withhold an interim dividend, signalling cautious optimism.

Vinyl Group Ltd has reported a robust 49% increase in revenue for the first half of FY26, alongside a significant reduction in net loss, driven by strategic acquisitions and AI integration.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Excelsior Capital Limited reported a $2.08 million loss for the half-year ending December 2025 as it moves to wind up operations, yet declared a substantial fully franked interim dividend.

TerraCom Limited reported a significant half-year loss amid falling coal prices and production challenges, completing a $56 million capital raise to strengthen its financial position.

HALO Technologies reports a strategic pivot towards APAC growth and a UK business model overhaul, alongside a 16% revenue decline and increased net loss in FY25.

Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.

RBR Group Limited narrowed its half-year loss to $588,746 as Mozambique LNG project activities resumed, underpinning cautious optimism amid ongoing funding challenges.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

Provaris Energy reported a 59% increase in its half-year loss to $2.09 million, driven by higher project development costs amid progress in hydrogen and carbon capture technologies. The company raised over $3.5 million in capital and is advancing key milestones for its hydrogen shipping and liquid CO2 tank projects.